Correction: Medication adherence and illness perception among diabetic patients in Upper Egypt Authors: Zeinab G. Abdelhamid, Doaa Mazen Abdel‑Salam, Ghada A. Mohamed, Hosnia S. Abd El‑Megeed Published: 2026 Correction: BMC Endocr Disord (2025) 25:223 10.1186/s12902-025-01966-5 Following publication of the original article [1], the corrections below have been made to ensure accurate description and attribution of the MMAS 8 instrument publication review. In the ‘‘Subjects and Methods’’ section under the subheading “Data collection tool” subsection, the 7th sentence:The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 7 or 6 indicates medium adherence, and a score of less than 6 indicates low adherence [19]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [20].Has been replaced with:Each ‘‘no’’ response is rated as 1 and each ‘‘yes’’ response is rated as 0 except for item 5, in which each ‘‘yes’’ response is rated as 1 and each ‘‘no’’ response is rated as 0. For Item 8, the code (0–4) must be standardized by dividing the result by 4 to calculate a summated score. The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 6-<8 indicates medium adherence, and a score of less than 6 indicates low adherence [19–21]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [22]. Permission to use the scale was granted by Dr. Donald Morisky, the copyright holder of the instrument.Two new references [2, 3] have been added accordingly in the original article as:[20] Berlowitz DR, Foy CG, Kazis LE, Bolin L, Lonroy LB, Fitzpatrick P, et al. for the SPRINT Study Research Group. Impact of Intensive Blood Pressure Therapy on Patient-Reported Outcomes: Outcomes Results from the SPRINT Study. N Engl J Med. 2017; 377:733–744.[21] Bress AP, Bellows BK, King J, Hess R Beddhu S, Zhang Z, et al. for the SPRINT Research Group and the SPRINT Economics and Health Related Quality of Life Subcommittee. Cost- Effectiveness of Intensive versus Standard Blood Pressure Control. N Engl J Med. 2017; 377:745–755.The caption of Fig. 1 has been updated from:Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt.To:Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt ©MMAS 2006 www.adherence.cc.The following sentence has been added to the end of acknowledgement section: “The authors would like to sincerely thank Dr. Donald Morisky for granting permission to use the Morisky Medication Adherence Scale (MMAS) in this study. ©MMAS 2006 www.adherence.cc”. In the ‘‘Subjects and Methods’’ section under the subheading “Data collection tool” subsection, the 7th sentence:The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 7 or 6 indicates medium adherence, and a score of less than 6 indicates low adherence [19]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [20].Has been replaced with:Each ‘‘no’’ response is rated as 1 and each ‘‘yes’’ response is rated as 0 except for item 5, in which each ‘‘yes’’ response is rated as 1 and each ‘‘no’’ response is rated as 0. For Item 8, the code (0–4) must be standardized by dividing the result by 4 to calculate a summated score. The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 6-<8 indicates medium adherence, and a score of less than 6 indicates low adherence [19–21]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [22]. Permission to use the scale was granted by Dr. Donald Morisky, the copyright holder of the instrument. In the ‘‘Subjects and Methods’’ section under the subheading “Data collection tool” subsection, the 7th sentence: The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 7 or 6 indicates medium adherence, and a score of less than 6 indicates low adherence [19]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [20]. Has been replaced with: Each ‘‘no’’ response is rated as 1 and each ‘‘yes’’ response is rated as 0 except for item 5, in which each ‘‘yes’’ response is rated as 1 and each ‘‘no’’ response is rated as 0. For Item 8, the code (0–4) must be standardized by dividing the result by 4 to calculate a summated score. The MMAS-8 has a total score range of 0 to 8, where a score of 8 indicates high adherence, a score of 6-<8 indicates medium adherence, and a score of less than 6 indicates low adherence [19–21]. The Arabic version of MMAS-8 has adequate internal consistency (α = 0.70) [22]. Permission to use the scale was granted by Dr. Donald Morisky, the copyright holder of the instrument. Two new references [2, 3] have been added accordingly in the original article as:[20] Berlowitz DR, Foy CG, Kazis LE, Bolin L, Lonroy LB, Fitzpatrick P, et al. for the SPRINT Study Research Group. Impact of Intensive Blood Pressure Therapy on Patient-Reported Outcomes: Outcomes Results from the SPRINT Study. N Engl J Med. 2017; 377:733–744.[21] Bress AP, Bellows BK, King J, Hess R Beddhu S, Zhang Z, et al. for the SPRINT Research Group and the SPRINT Economics and Health Related Quality of Life Subcommittee. Cost- Effectiveness of Intensive versus Standard Blood Pressure Control. N Engl J Med. 2017; 377:745–755. Two new references [2, 3] have been added accordingly in the original article as: [20] Berlowitz DR, Foy CG, Kazis LE, Bolin L, Lonroy LB, Fitzpatrick P, et al. for the SPRINT Study Research Group. Impact of Intensive Blood Pressure Therapy on Patient-Reported Outcomes: Outcomes Results from the SPRINT Study. N Engl J Med. 2017; 377:733–744. [21] Bress AP, Bellows BK, King J, Hess R Beddhu S, Zhang Z, et al. for the SPRINT Research Group and the SPRINT Economics and Health Related Quality of Life Subcommittee. Cost- Effectiveness of Intensive versus Standard Blood Pressure Control. N Engl J Med. 2017; 377:745–755. The caption of Fig. 1 has been updated from:Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt.To:Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt ©MMAS 2006 www.adherence.cc. The caption of Fig. 1 has been updated from: Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt. To: Fig. 1 Medication Adherence among diabetic patients attending Diabetes Clinic in Upper Egypt ©MMAS 2006 www.adherence.cc. The following sentence has been added to the end of acknowledgement section: “The authors would like to sincerely thank Dr. Donald Morisky for granting permission to use the Morisky Medication Adherence Scale (MMAS) in this study. ©MMAS 2006 www.adherence.cc”. The following sentence has been added to the end of acknowledgement section: “The authors would like to sincerely thank Dr. Donald Morisky for granting permission to use the Morisky Medication Adherence Scale (MMAS) in this study. ©MMAS 2006 www.adherence.cc”. The original article [1] has been updated.